Encyclopedia of Biophysics

Living Edition
| Editors: Gordon Roberts, Anthony Watts, European Biophysical Societies

(Glyco)Protein Folding Disorders

  • Elizabeth HounsellEmail author
Living reference work entry
DOI: https://doi.org/10.1007/978-3-642-35943-9_102-1



The term “protein folding disorders” (PFD) was introduced for a small group of proteins that misfold after biosynthesis producing pathological symptoms, for example, by depositing in inappropriate places. Of these proteins, three can be normally or sometimes N-glycosylated hence the term “(glyco)protein folding disorders” (GFD). However one of these, the Aβ precursor glycoprotein providing the 40, 41, or 42 amino acid residue fragments called amyloid-β-protein (Aβ) that are found in the plaques of patients with Alzheimer’s disease (AD), is also O-GlcNAcylated and many other proteins can also be, which results in misfolding and tissue deposition.


The term “PFD” can also now be applied to many more proteins, as we find out more about their complicated life stories. For example, in Huntington’s Disease (HD), the addition at gene level of repeat CAG means that the protein can be biosynthesized with a long Gln tail. This is somewhat...

This is a preview of subscription content, log in to check access.


  1. Alavi A, Axford JS (1995) Glycoimmunlogy, Advances in experimental medicine and biology, vol 376. Plenum Press, New YorkCrossRefGoogle Scholar
  2. Brooks SA, Dwek MV, Schumacher U (2002) Functional and molecular glycobiology. BIOS Scientific, OxfordGoogle Scholar
  3. Hounsell EF (2010) NMR spectroscopy of carbohydrates, lipids and membranes. In: Webb G (ed) Specialist reports in NMR spectroscopy. Royal Society of Chemistry, CambridgeGoogle Scholar
  4. Lehmann S, Harris DA (1997) Blockade of glycosylation promotes acquisition of scrapie-like properties by the prion protein in cultured cells. J Biol Chem 272:21479–21487CrossRefPubMedGoogle Scholar
  5. Miyata T, Inagi R, Iida Y, Sato M, Yamada N, Oda O, Maeda K, Seo H (1994) Involvement of β-2 microglobulin modified with advanced glycation end products in the pathogenesis of haemodialysis-associated amyloidosis. Induction of human monocyte chemotaxis and macrophage secretion of tumour necrosis factor-α and interleukin-1. J Clin Invest 93:521–528CrossRefPubMedPubMedCentralGoogle Scholar
  6. Omtvedt LA, Bailey D, Renouf DV, Davies MJ, Paramonov NA, Haavik S, Husby G, Sletter K, Hounsell EF (2000) Glycosylation of immunoglobulin light chains associated with amyloidosis. Amyloid Int J Clin Invest 7:227–244Google Scholar
  7. Routier FH, Hounsell EF, Rudd PM, Takahashi N, Bond A, Hay FC, Alavi A, Axford JS, Jeffris R (1998) Quantitation of the oligosaccharides of human serum IgG from patients with rheumatoid arthritis: a critical evaluation of different methods. J Immunol Methods 213(2):113–130CrossRefPubMedGoogle Scholar
  8. Vitek MP, Bhattacharya K, Glendening JM, Stopa E, Vlassara H, Bucala R, Manogue K, Cerami A (1994) Advanced glycation end products contribute to amyloidosis in Alzheimer’s disease. Proc Natl Acad Sci U S A 91:4766–4770CrossRefPubMedPubMedCentralGoogle Scholar
  9. Voet D, Voet JD, Pratt CW (2008) Principles of biochemistry. Wiley, HobokenGoogle Scholar
  10. Wang JZ, Grundke-Iqbal I, Iqbal K (1996) Glycosylation of microtubule-associated protein tau: an abnormal posttranslational modification in Alzheimer’s disease. Nat Med 2:871–875CrossRefPubMedGoogle Scholar
  11. Wong NKC, Renouf DV, Lehmann S, Hounsell EF (2000) Glycosylation of prions and its effects on protein conformation relevant to amino acid mutations. J Mol Graph Model 18:126–134CrossRefPubMedGoogle Scholar

Copyright information

© European Biophysical Societies' Association (EBSA) 2018

Authors and Affiliations

  1. 1.School of Biological and Chemical SciencesBirkbeck College, University of LondonLondonUK

Section editors and affiliations

  • Elizabeth Hounsell
    • 1
  1. 1.School of Biological and Chemical SciencesBirkbeck College, University of LondonLondonUK